Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease BurdenPRNewsWire • 09/23/25
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive DisorderPRNewsWire • 09/22/25
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TranscriptSeeking Alpha • 09/17/25
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025PRNewsWire • 09/16/25
Neurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Neurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/03/25
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth ConferencePRNewsWire • 08/06/25
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 EarningsZacks Investment Research • 07/30/25
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 07/30/25
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic ConditionPRNewsWire • 07/15/25
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025PRNewsWire • 07/15/25
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual MeetingPRNewsWire • 07/14/25
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025PRNewsWire • 07/14/25
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial ResultsPRNewsWire • 07/09/25
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor AntagonistPRNewsWire • 06/30/25
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease ChoreaPRNewsWire • 06/27/25